SUCCINCT: an open-label, single-arm, non-randomised, Phase 2 Trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma

Geldart, T. et al. (2015) SUCCINCT: an open-label, single-arm, non-randomised, Phase 2 Trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology, 67(4), pp. 599-602. (doi: 10.1016/j.eururo.2014.11.003)

Full text not currently available from Enlighten.

Abstract

Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC chemotherapy (SGC regimen). Overall, 63 treatment-naïve participants were recruited and received up to six 21-d cycles of cisplatin 70 mg/m2 (intravenously [IV], day 1) and gemcitabine 1000 mg/m2 (IV, days 1 and 8) combined with sunitinib 37.5 mg (orally, days 2–15). Following review of toxicity after the first six patients, the sunitinib dose was reduced to 25 mg for all patients. Overall response rate was 64%, with response noted in 37 of 58 patients. At 6 mo, 30 of 58 assessable patients (52%; 90% confidence interval [CI], 40–63%) were progression free. Median overall survival was 12 mo (95% CI, 9–15) and was heavily influenced by Bajorin prognostic group. Grade 3–4 toxicities were predominantly haematologic and limited the deliverability of the triple SGC regimen. The trial did not meet its prespecified primary end point of >60% patients progression free at 6 mo. Cumulative myelosuppression led to treatment delays of gemcitabine and cisplatin and dose reduction and/or withdrawal of sunitinib in the majority of cases. The triple-drug combination was not well tolerated. Phase 3 evaluation of the triple SGC regimen in advanced transitional cell carcinoma is not recommended.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Geldart, T., Chester, J., Casbard, A., Crabb, S., Elliott, T., Protheroe, A., Huddart, R. A., Mead, G., Barber, J., Jones, R. J., Smith, J., Cowles, R., Evans, J., and Griffiths, G.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:European Urology
Publisher:Elsevier B.V.
ISSN:0302-2838
ISSN (Online):1873-7560

University Staff: Request a correction | Enlighten Editors: Update this record